Pharmacokinetics and Ex Vivo Antimalarial Activity of Artesunate-Amodiaquine plus Methylene Blue in Healthy Volunteers

What Was Tested

The paper reports a study of Methylene blue (non-peptide stack partner), published as a randomized controlled trial.

High rates of artemisinin-based combination therapy (ACT) failures in the treatment of Plasmodium falciparum malaria in Southeast Asia have led to triple-drug strategies to extend the useful life of ACTs.

Who Took Part

According to the abstract, 15 volunteers were involved.

By PubMed's age tags, the people studied were young adults and adults, both men and women.

How the Study Was Run

In design terms this was a randomized, open-label and crossover study.

The volunteers were allocated by chance, so the Methylene blue (non-peptide stack partner) group and the comparison group should start out alike.

Being open-label, the Methylene blue (non-peptide stack partner) study did not mask who received what.

Each person switched between Methylene blue (non-peptide stack partner) and the comparison at some point, usually with a gap in between.

The methods mention a period of 28 days.

What Was Measured

The subject headings attached to it are Amodiaquine, Antimalarials, Artemisinins, Artesunate, Drug Combinations, Healthy Volunteers and Methylene Blue.

The authors tagged it with the keywords artesunate-amodiaquine and ex vivo antimalarial activity.

What This Means in Plain Language

The paper is a randomized, open-label and crossover study of Methylene blue (non-peptide stack partner) in 15 volunteers over 28 days.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 2020 (Antimicrobial agents and chemotherapy), a journal based in United States.

More context: the Methylene blue (non-peptide stack partner) compound page, all human trials.